Congresses and Publications

Zanubrutinib + Obinutuzumab Vs Obinutuzumab in Relapsed/Refractory Follicular Lymphoma: Final Analysis of ROSEWOOD

Number Needed to Treat to Avoid Progression or Death in Relapsed/Refractory Chronic Lymphocytic Leukemia Patient Preferences and Factors Affecting Patient Treatment Decisions for Chronic Lymphocytic Leukemia in Japan

JSMO 2026 Abstract: ALPINE LTE1 Zanu Patients

Evaluating Patient Preferences for Chronic Lymphocytic Leukemia in Korea: A Discrete Choice Experiment

Patient Preferences For Chronic Lymphocytic Leukemia (CLL) In Korea: A Discrete Choice Experiment

A Comparison of Tislelizumab Plus Chemotherapy vs Programmed Cell Death Protein-1 (PD-1) Inhibitor Monotherapy in First‑Line Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death-Ligand 1 (PD-L1) ≥50% PD-(L)1 inhibitors for first-line treatment of extensive-stage small-cell lung cancer in Asian and non-Asian patients: a meta-analysis RATIONALE-304: Baseline Tumor Genomic Alterations According to Programmed Death-Ligand 1 Subgroups in Non-Squamous Non-Small Cell Lung Cancer Treated With First-Line Tislelizumab Plus Chemotherapy vs Chemotherapy Alone RATIONALE-315: Association of Residual Viable Tumor and Nodal Status With Survival Benefit for Patients With Resectable Non-Small Cell Lung Cancer Treated With Perioperative Tislelizumab

PD-(L)1 inhibitors for first-line treatment of ES-SCLC in Asian and non-Asian patients: a meta-analysis RATIONALE-304: baseline tumour genomic alterations according to programmed death-ligand 1 (PD-L1) subgroups in nonsquamous non-small cell lung cancer (nsq- NSCLC) treated with first-line tislelizumab (TIS) plus chemotherapy (CT) vs CT alone RATIONALE-315: Association of residual viable tumor (RVT) and nodal status with survival benefit for patients (Pts) with resectable non-small cell lung cancer (NSCLC) treated with perioperative tislelizumab (TIS) comparison of tislelizumab (TIS) plus chemotherapy (CT) vs programmed cell death protein-1 (PD-1) inhibitor monotherapy in first-line (1L) non-squamous (nsq) non-small cell lung cancer (nsclc) patients (pts) with programmed cell-death ligand 1 (PD-L1) ≥50%

Outcomes During BTKi Treatment for Chronic Lymphocytic Leukemia: Insights From Remote Therapeutic Monitoring Real-World Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treatment Patterns at Florida Cancer Specialists & Research Institute Among Patients Receiving Zanubrutinib Immediately Following Prior BTKi Therapy Real-World Treatment Patterns and Patient Characteristics of Venetoclax Combination Time-Limited Therapy for Chronic Lymphocytic Leukemia Treatment Patterns and Outcomes Among Patients Treated With Next-Generation Covalent Bruton Tyrosine Kinase Inhibitors (cBTKi) in Chronic Lymphocytic Leukemia (CLL) at the University of California San Francisco Health (UCSF) System

Exploratory biomarker analysis of the phase 3 RATIONALE 305 trial: First-line (1L) tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT for advanced gastric cancer/gastro-oesophageal junction adenocarcinoma (GC/GEJC) Tislelizumab + chemotherapy vs placebo + chemotherapy in patients with locally advanced esophageal squamous cell carcinoma: RATIONALE-306 subgroup analysis

Comparative efficacy and safety of tislelizumab (TIS) vs other anti–PD-1 treatments in first-line (1L) gastric or gastroesophageal junction cancer (GC/GEJC): A network meta-analysis (NMA) Recurrent patient-reported outcome (PRO)-based deterioration predicts overall sur-vival (OS) in patients with advanced gastric adenocarcinoma with PD-L1 score of ≥5%: Results from the RATIONALE-305 trial Safety and Efficacy of Zanubrutinib (Zanu) in a Subgroup of Older Patients (≥75 Years) With Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) From the Phase 3 SEQUOIA Study Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in HER2-negative ad-vanced or metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): RATIONALE-305 study minimum 3-year survival follow-up Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in patients (pts) with locally advanced (LA) esophageal squamous cell carcinoma (ESCC): RATIONALE-306 subgroup analysis